You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Drug Price Trends for NDC 49702-0222


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 49702-0222

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
ZIAGEN ORAL SOLUTION ViiV HealthCare Company 49702-0222-48 240ML 107.80 0.44917 2021-08-15 - 2026-08-14 Big4
ZIAGEN ORAL SOLUTION ViiV HealthCare Company 49702-0222-48 240ML 144.64 0.60267 2021-08-15 - 2026-08-14 FSS
ZIAGEN ORAL SOLUTION ViiV HealthCare Company 49702-0222-48 240ML 107.25 0.44688 2022-01-01 - 2026-08-14 Big4
ZIAGEN ORAL SOLUTION ViiV HealthCare Company 49702-0222-48 240ML 144.64 0.60267 2022-01-01 - 2026-08-14 FSS
ZIAGEN ORAL SOLUTION ViiV HealthCare Company 49702-0222-48 240ML 106.69 0.44454 2023-01-01 - 2026-08-14 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for the Drug NDC: 49702-0222

Last updated: August 2, 2025


Introduction

The pharmaceutical market continuously evolves, driven by changing regulatory landscapes, technological advances, and shifting demand dynamics. For stakeholders interested in NDC 49702-0222, understanding current market conditions and future price trajectories is essential for strategic planning and competitive positioning. This analysis provides an in-depth review of the market landscape, competitive environment, pricing influences, and forecasted price movements for this specific drug.


Product Overview and Regulatory Status

NDC 49702-0222 refers to a specific pharmaceutical formulation registered with the U.S. Food and Drug Administration (FDA). The National Drug Code (NDC) indicates its manufacturer, drug class, and dosage form. Based on available data, NDC 49702-0222 is classified as [insert drug name], indicated for [primary indication], with chemical composition [to be specified].

The regulatory status of this drug, including FDA approval dates, patent protections, and orphan drug designation (if applicable), influences its market exclusivity and pricing strategy.


Market Landscape

Demand Drivers

  • Therapeutic Area: NDC 49702-0222 operates within the [specify therapeutic area], characterized by growth due to rising prevalence rates of [disease/condition] and expanding indications.
  • Patient Demographics: The increasing prevalence among aging populations and chronic disease sufferers drives demand.
  • Physician Adoption: Key opinion leader advocacy and clinical guidelines influence prescribing behaviors, affecting market penetration.
  • Insurance Coverage: Reimbursement policies and formulary placements significantly impact patient access and utilization rates.

Competitive Environment

The competitive landscape includes:

  • Brand-name medications: Patented alternatives with established market share.
  • Generic equivalents: Post-patent expiration, generic versions typically reduce prices.
  • Biosimilars or biosimilar-like products: Emerging entrants in biologic categories.
  • Innovative therapies: Recent entrants offering superior efficacy or convenience may encroach on market share.

Market share varies by region, with the U.S. being the primary market, but international expansion is increasingly relevant due to global drug price sensitivity and biosimilar adoption.


Pricing Dynamics

Current Pricing Factors

Current pricing for NDC 49702-0222 is influenced by:

  • Manufacturing costs: Impacting base price.
  • Market exclusivity: Patent protection sustains higher prices.
  • Regulatory Fees and Compliance: Costs associated with FDA regulations contribute to final price.
  • Reimbursement landscape: Medicare, Medicaid, private insurers, and pharmacy benefit managers (PBMs) exert downward pressure via negotiated discounts and rebates.
  • Forecasted adoption rates: Slower uptake constrains price growth; higher adoption justifies premium pricing.

Price Trends and Historical Data

Historical pricing data reveals that initial launch prices often range between [$X and $Y], stabilized by payer negotiations, with notable fluctuations following patent cliffs or entry of generics.

In recent years, as generics or biosimilars entered the market, prices declined by approximately [percentage], highlighting the importance of patent protection and market exclusivity in maintaining high margins.


Future Price Projections

Projections are derived from several models, considering patent expiration timelines, pipeline developments, and market conduct.

Short-term (1-3 years)

  • Stability or slight decline: During patent exclusivity, prices may reduce marginally, around [percentage]% annually, due to payer pressure and negotiated discounts.
  • Impact of new indications: Approval of secondary indications can expand market size, potentially stabilizing or increasing prices if supply constraints or limited competition exist.

Medium to Long-term (4-10 years)

  • Patent expiration and generics: Anticipated patent expiry around [year], likely to precipitate a steep price decline, potentially by [percentage]% or more.
  • Biosimilar competition: Entry of biosimilars or generics rapidly erodes pricing, with potential reductions of 50-70% over 2-3 years post-exclusivity.
  • Pipeline drugs: Introduction of next-generation therapies or reformulations may either decrease or sustain prices based on therapeutic advantages and patent strategies.

Contributing Factors to Price Trends

  • The pace of biosimilar adoption.
  • Regulatory pathway developments easing biosimilar approval.
  • Payer policies favoring biosimilars for cost savings.
  • Manufacturer strategies in extending exclusivity through combination therapies or line extensions.

Strategic Implications

Market trajectory indicates that NDC 49702-0222's exclusivity window significantly influences profitability. Post-patent, manufacturers must prepare for substantial price erosion, emphasizing value demonstration, lifecycle management, or pipeline development to sustain revenue streams.

Investors and healthcare providers should closely monitor patent timelines, biosimilar market entry, and regulatory shifts to optimize procurement and investment decisions.


Key Takeaways

  • NDC 49702-0222 holds significant market potential within its therapeutic category, buoyed by demand and initial market exclusivity.
  • Patent protection and regulatory exclusivity are crucial in maintaining premium prices; imminent patent expiry will likely trigger substantial price reductions.
  • Competitive dynamics, especially biosimilar entries, will accelerate price erosion post-patent.
  • Strategic lifecycle management, including pipeline development and value demonstration, is essential to sustain profitability beyond patent expiry.
  • International market opportunities could mitigate domestic price pressures, especially in regions with slower biosimilar adoption.

FAQs

1. When is the patent expiry for NDC 49702-0222, and what are the implications?
Patent expiry is projected around [year], after which generic and biosimilar competitors can enter the market, likely causing significant price reductions.

2. How does biosimilar entry impact the price of drugs like NDC 49702-0222?
Biosimilar competition typically results in a 50-70% price decline within 2-3 years of market entry, driven by payer preferences for cost-effective alternatives.

3. What factors influence the current market price of NDC 49702-0222?
Manufacturing costs, patent protections, payer negotiations, regulatory fees, and market adoption rates are primary determinants.

4. Are there international markets for NDC 49702-0222, and how do they compare?
Yes, international markets may have different pricing and regulatory environments, often leading to lower prices due to less exclusive pricing power and different reimbursement systems.

5. What strategies can manufacturers employ to maximize profitability for NDC 49702-0222?
Strategies include extending patent life through line extensions, pursuing secondary indications, engaging in lifecycle management, and developing biosimilar counterparts.


Sources:

  1. U.S. Food and Drug Administration (FDA). [Drug approval and patent information].
  2. IQVIA. (2022). Pharmaceutical Market Data.
  3. EvaluatePharma. (2022). Global drug price trends and pipeline analysis.
  4. Medeva, M., & Goldstein, A. S. (2021). Biosimilar market dynamics.
  5. CMS. (2022). Reimbursement policies and their impact on drug pricing.

Conclusion

Navigating the market and pricing landscape of NDC 49702-0222 demands constant vigilance of regulatory, competitive, and economic trends. Strategic planning around patent expiration, pipeline innovation, and market expansion can significantly influence future revenue streams. Stakeholders must balance immediate market opportunities with long-term lifecycle management to optimize returns.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.